NCT01000649 - Effects of the V1a Agonist FE 202158 in Patients With Septic Shock | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

September 30, 2011

Conditions

Septic Shock

Interventions

DRUG

FE 202158 1.25

FE 202158 at dose 1.25 ng/kg/min infused.

DRUG

FE 202158 2.5

FE 202158 at dose 2.5 ng/kg/min infused.

DRUG

FE 202158 3.75

FE 202158 at dose 3.75 ng/kg/min infused.

OTHER

Placebo

Isotonic saline infused.

Trial Locations (16)

Christiana Care Health System, Newark

Baystate Medical Center, Springfield

Division of Education and Research SMDC Health System, Duluth

Cooper University Hospital, Camden

Mount Sinai School of Medicine, New York

Baylor College of Medicine, Houston

Clinique Universitaire St-Luc, Brussels

Erasme Hospital (Free University of Brussels), Brussels

University Hospital Vrije Universiteit, Brussels

Service des Soins Intensits, Dinant

Royal Columbian Hospital, Vancouver

St. Paul´s Hospital, Vancouver

Bispebjerg Hospital, Bispebjerg

Rigshospitalet, Copenhagen

Hillerød Hospital, Hillerød

Hvidovre Hospital, Hvidovre